- Home
- DSP vs ARMP Comparison
DSP vs ARMP Comparison
Compare DSP & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSP | ARMP |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 125.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DSP | ARMP |
|---|---|---|
| Price | $10.59 | $7.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $19.44 | $9.00 |
| AVG Volume (30 Days) | ★ 304.3K | 99.2K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.49 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $324,131,000.00 | $5,054,000.00 |
| Revenue This Year | $16.39 | $8.43 |
| Revenue Next Year | $14.89 | N/A |
| P/E Ratio | $107.44 | ★ N/A |
| Revenue Growth | ★ 22.97 | N/A |
| 52 Week Low | $8.11 | $0.90 |
| 52 Week High | $26.33 | $16.34 |
Technical Indicators
Market Signals| Indicator | DSP | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 63.33 | 65.33 |
| Support Level | $9.32 | $6.81 |
| Resistance Level | $10.93 | $7.40 |
| Average True Range (ATR) | 0.58 | 0.67 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 86.44 | 89.99 |
Price Performance
Historical ComparisonAbout DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.